Deal Snaps
BioTech startup Cerecin secures $40 million in Series IIA round of funding
Cerecin, a Singapore-based biotech startup that focuses on neurotherapeutics, has raised $40 million in Series IIA funding round.
April 3, 2022
Bayfront's Library
Explore through our library for our market insights, research articles, case studies and more.
Alzheimers Disease